Retatrutide vs Tirzepatide vs Semaglutide: Why Clav Chose Triple-Agonist

The Three Generations of GLP Research

GLP receptor agonist research has produced three distinct generations of compounds, each adding receptor coverage and improving weight loss outcomes. Clavicular's choice of Retatrutide is data-driven — and the data gap is significant.

The Numbers

Compound

Receptors

Trial

Duration

Weight Loss

Semaglutide	GLP-1	STEP-1	68 weeks	−14.9%
Tirzepatide	GLP-1 + GIP	SURMOUNT-1	72 weeks	−20.9%
Retatrutide	GLP-1 + GIP + GcgR	Phase 2	48 weeks	−28.7%

Retatrutide's Phase 2 result (48 weeks) already exceeds tirzepatide's Phase 3 result (72 weeks). The trajectory at 48 weeks had not plateaued.

Why Each Generation Is Stronger

Semaglutide → GLP-1 receptor only: Hypothalamic appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion. Single mechanism, well-characterized, proven CV outcomes (SELECT trial).

Tirzepatide → adds GIP receptor: GIP receptor agonism adds insulin sensitization, direct adipocyte lipid effects, and synergistic GLP-1R potentiation. The dual mechanism produces ~6 percentage points more fat loss than semaglutide in head-to-head data.

Retatrutide → adds Glucagon receptor: Glucagon receptor agonism is the critical addition. It drives:

• Hepatic beta-oxidation of fatty acids
• Brown adipose tissue thermogenesis
• Visceral fat mobilization

These are active fat-burning mechanisms — not just appetite suppression. The body literally burns more fat at rest. This is why Retatrutide produces ~8 percentage points more loss than tirzepatide's best result.

Clavicular's Reasoning

The Clav stack uses Retatrutide because when you're designing a research protocol for maximum body recomposition, you use the compound with the most receptor coverage and the best data. Semaglutide and tirzepatide are excellent — Retatrutide is a different category.

Research use only.